With respect to CASP9 -293 del polymorphism, the frequency of heterozygous (+/−) genotype was elevated among controls as compared to cases and was associated with reduced risk for CML development under co-dominant, dominant and over-dominant models. The gene discussed is CASP9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.